<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dimerix Limited — News on 6ix</title>
<link>https://6ix.com/company/dimerix-ltd</link>
<description>Latest news and press releases for Dimerix Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 03:33:27 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dimerix-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836639078dffbe2df15cd0c.webp</url>
<title>Dimerix Limited</title>
<link>https://6ix.com/company/dimerix-ltd</link>
</image>
<item>
<title>Dimerix Quarterly Activities Report and Appendix 4C</title>
<link>https://6ix.com/company/dimerix-ltd/news/dimerix-quarterly-activities-report-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dimerix-quarterly-activities-report-and-appendix-4c</guid>
<pubDate>Thu, 30 Apr 2026 03:33:27 GMT</pubDate>
<description>Dimerix Quarterly Activities Report and Appendix 4C</description>
</item>
<item>
<title>BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE</title>
<link>https://6ix.com/company/dimerix-ltd/news/blinded-assessment-of-action3-statistical-assumptions-complete</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/blinded-assessment-of-action3-statistical-assumptions-complete</guid>
<pubDate>Tue, 28 Apr 2026 02:17:00 GMT</pubDate>
<description>Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announced that the blinded review of ACTION3 Phase 3 study data to confirm statistical assumptions of the primary endpoint has been successfully completed. This blinded review confirms that the ACTION3 study remains appropriately statistically powered to detect the treatment effect for the proteinuria primary endpoint. Having the ACTION3 Phase 3 study with >90% statistical power for its</description>
</item>
<item>
<title>Dimerix to Conduct Review of ACTION3 Statistical Assumptions</title>
<link>https://6ix.com/company/dimerix-ltd/news/dimerix-to-conduct-review-of-action3-statistical-assumptions</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dimerix-to-conduct-review-of-action3-statistical-assumptions</guid>
<pubDate>Mon, 16 Mar 2026 01:50:04 GMT</pubDate>
<description>Dimerix to Conduct Review of ACTION3 Statistical Assumptions</description>
</item>
<item>
<title>Dimerix Phase 3 Trial Last Patient Receives First Dose</title>
<link>https://6ix.com/company/dimerix-ltd/news/dimerix-phase-3-trial-last-patient-receives-first-dose</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dimerix-phase-3-trial-last-patient-receives-first-dose</guid>
<pubDate>Tue, 10 Mar 2026 02:43:07 GMT</pubDate>
<description>Dimerix Phase 3 Trial Last Patient Receives First Dose</description>
</item>
<item>
<title>Appendix 4D and Half Year Financial Report</title>
<link>https://6ix.com/company/dimerix-ltd/news/appendix-4d-and-half-year-financial-report-48</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/appendix-4d-and-half-year-financial-report-48</guid>
<pubDate>Thu, 26 Feb 2026 03:51:08 GMT</pubDate>
<description>Appendix 4D and Half Year Financial Report</description>
</item>
<item>
<title>Quarterly Appendix 4C and Activities Report</title>
<link>https://6ix.com/company/dimerix-ltd/news/quarterly-appendix-4c-and-activities-report</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/quarterly-appendix-4c-and-activities-report</guid>
<pubDate>Thu, 29 Jan 2026 03:59:24 GMT</pubDate>
<description>Quarterly Appendix 4C and Activities Report</description>
</item>
<item>
<title>BioMarin to acquire Dimerix US Partner, Amicus Therapeutics</title>
<link>https://6ix.com/company/dimerix-ltd/news/biomarin-to-acquire-dimerix-us-partner-amicus-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/biomarin-to-acquire-dimerix-us-partner-amicus-therapeutics</guid>
<pubDate>Mon, 22 Dec 2025 03:37:05 GMT</pubDate>
<description>BioMarin to acquire Dimerix US Partner, Amicus Therapeutics</description>
</item>
<item>
<title>DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT</title>
<link>https://6ix.com/company/dimerix-ltd/news/dmx-200-action3-phase-3-070200848</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dmx-200-action3-phase-3-070200848</guid>
<pubDate>Mon, 15 Dec 2025 07:02:00 GMT</pubDate>
<description>Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announces that the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) has now successfully completed the planned recruitment and dosing of the 286th adult patient[1].</description>
</item>
<item>
<title>DMX-200 ACTION3 Phase 3 Trial Completes Recruitment</title>
<link>https://6ix.com/company/dimerix-ltd/news/dmx-200-action3-phase-3-trial-completes-recruitment</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dmx-200-action3-phase-3-trial-completes-recruitment</guid>
<pubDate>Mon, 15 Dec 2025 03:06:06 GMT</pubDate>
<description>DMX-200 ACTION3 Phase 3 Trial Completes Recruitment</description>
</item>
<item>
<title>Successful Completion of Planned IDMC Review</title>
<link>https://6ix.com/company/dimerix-ltd/news/successful-completion-of-planned-idmc-review</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/successful-completion-of-planned-idmc-review</guid>
<pubDate>Wed, 19 Nov 2025 03:26:06 GMT</pubDate>
<description>Successful Completion of Planned IDMC Review</description>
</item>
<item>
<title>Successful PARASOL Collaboration Data Analysis Outcome</title>
<link>https://6ix.com/company/dimerix-ltd/news/successful-parasol-collaboration-data-analysis-outcome</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/successful-parasol-collaboration-data-analysis-outcome</guid>
<pubDate>Wed, 08 Oct 2025 01:58:12 GMT</pubDate>
<description>Successful PARASOL Collaboration Data Analysis Outcome</description>
</item>
<item>
<title>DMX-200 receives Orphan Drug Designation in Japan</title>
<link>https://6ix.com/company/dimerix-ltd/news/dmx-200-receives-orphan-drug-designation-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dmx-200-receives-orphan-drug-designation-in-japan</guid>
<pubDate>Tue, 30 Sep 2025 02:57:08 GMT</pubDate>
<description>DMX-200 receives Orphan Drug Designation in Japan</description>
</item>
<item>
<title>Appendix 4E and 2025 Annual Report</title>
<link>https://6ix.com/company/dimerix-ltd/news/appendix-4e-and-2025-annual-report-19</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/appendix-4e-and-2025-annual-report-19</guid>
<pubDate>Thu, 28 Aug 2025 03:28:03 GMT</pubDate>
<description>Appendix 4E and 2025 Annual Report</description>
</item>
<item>
<title>Dimerix receives 1st Development Milestone payment from FUSO</title>
<link>https://6ix.com/company/dimerix-ltd/news/dimerix-receives-1st-development-milestone-payment-from-fuso</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dimerix-receives-1st-development-milestone-payment-from-fuso</guid>
<pubDate>Mon, 30 Jun 2025 02:53:20 GMT</pubDate>
<description>Dimerix receives 1st Development Milestone payment from FUSO</description>
</item>
<item>
<title>ACTION3 Clinical Trial Milestone Recruitment Update</title>
<link>https://6ix.com/company/dimerix-ltd/news/action3-clinical-trial-milestone-recruitment-update</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/action3-clinical-trial-milestone-recruitment-update</guid>
<pubDate>Fri, 13 Jun 2025 03:19:17 GMT</pubDate>
<description>ACTION3 Clinical Trial Milestone Recruitment Update</description>
</item>
<item>
<title>1st ACTION3 site in Japan activated and milestone triggered</title>
<link>https://6ix.com/company/dimerix-ltd/news/1st-action3-site-in-japan-activated-and-milestone-triggered</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/1st-action3-site-in-japan-activated-and-milestone-triggered</guid>
<pubDate>Fri, 30 May 2025 02:46:13 GMT</pubDate>
<description>1st ACTION3 site in Japan activated and milestone triggered</description>
</item>
<item>
<title>Successful planned IDMC review of ACTION3 trial</title>
<link>https://6ix.com/company/dimerix-ltd/news/successful-planned-idmc-review-of-action3-trial</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/successful-planned-idmc-review-of-action3-trial</guid>
<pubDate>Thu, 22 May 2025 02:52:13 GMT</pubDate>
<description>Successful planned IDMC review of ACTION3 trial</description>
</item>
<item>
<title>Dimerix receives initial upfront payment from Amicus</title>
<link>https://6ix.com/company/dimerix-ltd/news/dimerix-receives-initial-upfront-payment-from-amicus</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dimerix-receives-initial-upfront-payment-from-amicus</guid>
<pubDate>Tue, 06 May 2025 02:47:24 GMT</pubDate>
<description>Dimerix receives initial upfront payment from Amicus</description>
</item>
<item>
<title>Investor Webinar and Presentation</title>
<link>https://6ix.com/company/dimerix-ltd/news/investor-webinar-and-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/investor-webinar-and-presentation</guid>
<pubDate>Thu, 01 May 2025 03:43:17 GMT</pubDate>
<description>Investor Webinar and Presentation</description>
</item>
<item>
<title>Dimerix Licenses DMX-200 in the US</title>
<link>https://6ix.com/company/dimerix-ltd/news/dimerix-licenses-dmx-200-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/dimerix-ltd/news/dimerix-licenses-dmx-200-in-the-us</guid>
<pubDate>Thu, 01 May 2025 03:31:05 GMT</pubDate>
<description>Dimerix Licenses DMX-200 in the US</description>
</item>
</channel>
</rss>